
By SaiyanMed Research Team · Updated 30 October 2026 (v2: regulatory record, competitor-claim audit and PAA answers added) · For laboratory research education only. Not for human or veterinary use. Nothing here is medical advice.
Quick answer: Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a registered heptapeptide with decades of Russian and preclinical literature[1][9]. “Adamax” is a market name, not a registered molecule. It is sold as at least two different structures: an acetylated Semax with a C-terminal adamantane carboxamide (~1032 Da) and an acetylated, Ala-Gly-extended nonapeptide (~984 Da)[3]. We found no peer-reviewed study and no registered trial on either[17][18]. The only formal document describing an adamantane-modified Semax is a Ferring patent application that reports no data on it, and its European family member has been withdrawn[4][5]. The one regulator document we found that names Adamax, a June 2025 New Zealand Medsafe submission, groups it with Semax as an ACTH analogue sold as a cognitive enhancer and says little is known about side effects[19]. So comparing Adamax and Semax is mostly a comparison between a body of evidence and a design hypothesis.
Key takeaways
- Adamax is a name, not a structure. Two circulating versions differ by a calculated 48 Da and are not interchangeable.
- The idea is borrowed, the data are not. Adding an adamantane unit at the C-terminus to block degradation is documented for a different peptide, P021[7]. Nobody has published equivalent data for Semax.
- The “adamantylglycine” label doesn’t fit. Vendors call the unit “adamantylglycine”, but the formula they quote matches a 3-amino-adamantane-1-carboxamide unit (calculated).
- Identity needs mass spec. A certificate that confirms identity only by HPLC retention-time match cannot tell the 1032 amide from its free acid, which is 0.98 Da heavier (calculated).
- No relation to bromantane, amantadine or memantine beyond sharing the adamantane skeleton[12][13][14].
Adamax vs Semax at a glance
| Semax | Adamax (as marketed) | |
|---|---|---|
| Identity | Met-Glu-His-Phe-Pro-Gly-Pro; PubChem CID 9811102, CAS 80714-61-0[1] | No CID or CAS. One vendor-deposited substance record with no structure[3] |
| Structure | Free N-terminus, free C-terminal acid | Version A: Ac-MEHFPGP–[adamantane carboxamide]. Version B: Ac-MEHFPGPAG-OH |
| Peer-reviewed studies | Many (degradation, metabolism, receptor and gene-expression work)[9][10] | None found under that name (PubMed, 30 Oct 2026)[17] |
| Registered trials | Not covered here | None found[18] |
| Formal design document | — | Ferring WO2023046336A1 mentions an adamantane derivative; no data on it[4] |
| Evidence for the adamantane idea | — | Indirect only: P021, a different peptide[7][6] |
| Human safety data | Limited, mostly Russian clinical literature; no trial registered on ClinicalTrials.gov[24] | None published[17][19] |
| U.S. FDA record | Not FDA-approved. On FDA’s list of nominations previously in compounding Category 2 that were withdrawn; reviewed by FDA’s compounding advisory committee on 24 July 2026[16][21] | Not named by FDA |
| Other regulators | Named by NZ Medsafe (2025) as an ACTH analogue[19] | Named by NZ Medsafe (2025) alongside Semax; classification decision deferred[19][20]. Not named by WADA (S0 is a catch-all)[15] |
What “Adamax” actually refers to
There is no compound called Adamax in PubChem’s compound database. A name search returns no CID. The only PubChem entry is a substance record deposited by a supplier, listing the synonym “Adamax” with the sequence Ac-Met-Glu-His-Phe-Pro-Gly-Pro-Ala-Gly-OH and no deposited structure[3]. Meanwhile, most retail listings and COAs describe a 1032 Da molecule with an adamantane unit. Some sell it as “Adamax 1032”[26].
Put simply: two different molecules are sold under the same name. The name itself appears to come from adamantane plus “max”. That’s a branding convention, not a chemical rule.
What does Adamax do? The honest answer
Nobody has published a measurement of what Adamax does. Under either structure, we found no binding, cell, animal, pharmacokinetic or human study[17][18]. Pages that rank for this question typically state that Adamax “raises BDNF”, “sensitises TrkB receptors”, is “more dopaminergic” or improves endurance. When we traced those statements, each was either uncited or described Semax experiments, then applied to Adamax without saying so. Medsafe’s own summary of the ACTH-analogue products says their “mechanism of action is often unknown”[19].
| Statement seen on ranking pages | Where the underlying data come from | Applies to Adamax? |
|---|---|---|
| Raises BDNF / acts via TrkB | Semax rodent studies; one 2007 hypothesis paper summarises them[23] | Not tested |
| Modulates dopamine release | Semax animal data (augmenting psychostimulant effects), as summarised in the same hypothesis paper[23] | Not tested |
| Longer half-life, better brain penetration | Patent aim statement; P021 stability data for a different peptide[4][7] | Not tested |
| “2–3× endurance vs other Semax analogues” | No source given | No evidence |
| A vasopressin, oxytocin or BPC-157 blend | No source given; contradicts every published formula | No: inconsistent with both structures |
Side effects: no human safety data exist for Adamax. Medsafe notes that for ACTH analogues as a class “little is known about their side effects or long-term effects”[19]. Side-effect lists on retail and app pages are borrowed from Semax or from user self-reports, not from studies of this molecule.
Regulatory record: what regulators have actually said
- U.S. FDA: Semax is not FDA-approved. FDA’s compounding-risk page now lists Semax (heptapeptide) among substances “previously in category 2” whose nominations were withdrawn by the nominators. The same entry still says compounded Semax “may pose risk for immunogenicity” and that FDA has “no, or limited, safety-related information” for proposed routes (page current as of 22 April 2026)[16]. FDA’s Pharmacy Compounding Advisory Committee discussed Semax on 24 July 2026 as a candidate for the 503A bulks list, for cerebral ischemia, migraine and trigeminal neuralgia[21]. An advisory discussion is not an FDA decision, and we did not find an FDA rule adding Semax to the bulks list. Adamax does not appear in these FDA records.
- New Zealand Medsafe: in a June 2025 submission, Medsafe proposed classifying ACTH analogues as prescription medicines, explicitly naming “Adamax and Semax (two peptide products currently marketed as cognitive enhancers)”[19]. In July 2025 the Medicines Classification Committee deferred its decision pending more information. A secretariat note then reported no objections from the cosmetics industry and repeated the recommendation[20].
- WADA: neither compound is named; S0 covers non-approved substances generally[15].
This is a record of public documents, not legal advice. Rules vary by country and change often.
What is Semax similar to? Semax vs Selank, structurally
Semax belongs to a small family of Russian-developed peptides that add a Pro-Gly-Pro (PGP) tail to a short bioactive fragment. Its closest relatives are its own capped forms and Selank:
| Peptide | Sequence | Parent fragment | Formula / avg MW |
|---|---|---|---|
| Semax | Met-Glu-His-Phe-Pro-Gly-Pro | ACTH(4-7) + PGP | C37H51N9O10S / 813.9[1] |
| N-Acetyl Semax amidate | Ac-MEHFPGP-NH2 | Capped Semax | C39H54N10O10S / 855.0[2] |
| Adamax, Version A | Ac-MEHFPGP-[adamantane carboxamide] | Capped Semax + cage | C50H69N11O11S / 1032.2 (calc.) |
| Selank | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Tuftsin (TKPR) + PGP | C33H57N11O9 / 751.9[22] |
“Which is better, Semax or Selank?” has no general answer. They share only the PGP tail. Selank’s core is the immunomodulatory tetrapeptide tuftsin, while Semax’s core comes from ACTH, so their literatures concern different questions. Which is “better for anxiety” is a clinical question that this research reference does not address. The choice for a laboratory comes down to which literature your protocol builds on. See our Selank vs N-Acetyl Selank Amidate guide for Selank’s structure and verification data.

Structure comparison: Semax, NA-Semax amidate and both Adamax versions
All values below except PubChem’s own Semax formula are calculated by us from the sequences with RDKit and standard monoisotopic masses (H⁺ = 1.00728). cLogP is RDKit’s Crippen estimate. It’s a rough comparison of lipophilicity, not a measured value.
| Molecule | Sequence / modification | Formula | Avg MW | Monoisotopic | [M+H]⁺ | [M+2H]²⁺ | cLogP (calc.) |
|---|---|---|---|---|---|---|---|
| Semax | H-MEHFPGP-OH | C37H51N9O10S | 813.93 | 813.3480 | 814.3552 | 407.6813 | −1.22 |
| N-Acetyl Semax amidate | Ac-MEHFPGP-NH2 | C39H54N10O10S | 854.98 | 854.3745 | 855.3818 | 428.1945 | −1.64 |
| Adamax, Version A (“1032”) | Ac-MEHFPGP-NH-Ad-CONH2 | C50H69N11O11S | 1032.23 | 1031.4899 | 1032.4971 | 516.7522 | −0.19 |
| Adamax, Version B (“984”) | Ac-MEHFPGPAG-OH | C44H61N11O13S | 984.10 | 983.4171 | 984.4244 | 492.7158 | −2.42 |
Some differences are worth spelling out (all calculated):
- Version A − N-Acetyl Semax amidate = +177.115 Da. That is exactly C11H15NO, the adamantane unit inserted before the terminal amide.
- Version A − Version B = +48.07 Da. On a mass spectrum the two can’t be confused.
- Version A − Semax = +218.14 Da (monoisotopic).
- On cLogP, Version A is the only form more lipophilic than Semax. Version B is the least lipophilic of the four, because it adds a free acid and two more amide bonds. Anyone buying Version B “for the adamantane” isn’t getting any adamantane.
Why “adamantylglycine” is probably the wrong name
Vendors often describe the C-terminal unit as “adamantylglycine”. Strictly, adamantylglycine is an α-amino acid, 2-amino-2-(adamantyl)acetic acid (C12H19NO2). Built into the chain as a residue with a terminal amide, it would give a formula of C51H71N11O11S, not the C50H69N11O11S that sellers quote (calculated). The quoted formula instead matches a 3-amino-adamantane-1-carboxamide unit. That is the same building block FDA’s GSRS lists in P021’s systematic name (“N-(3-(aminocarbonyl)tricyclo[3.3.1.1]dec-1-yl)”)[8]. The P021 papers call it “adamantylated glycine”[7], which is probably where the shorthand came from. This matters for verification. If a supplier’s drawing shows a true adamantylglycine, its expected mass is 14 Da higher.
Where the adamantane idea comes from
1. P021: the real evidence, for a different peptide
P021 is a small peptidomimetic derived from ciliary neurotrophic factor. Its developers added an “adamantylated glycine” at the C-terminus “to increase its blood–brain barrier permeability and decrease its degradation by carboxy peptidases”[7]. In the 2017 full-text paper, the molecule (Ac-DGGL^AG-NH2, MW 578.3) stayed more than 95% intact in simulated gastric juice at 30 minutes, about 100% intact in simulated intestinal fluid at 120 minutes, and stable in plasma for over 3 hours[7]. The work was done in mice, and the paper reports a stability profile, not a human pharmacokinetic study. The earlier 2010 FEBS Letters paper introduced the compound. We could only read its abstract, so we cite it only for the compound’s introduction[6].
What this does and doesn’t tell you: it shows the C-terminal adamantane strategy can protect a small peptide from carboxypeptidases. It says nothing about Semax, whose sequence, length and degradation pathways are different.
2. The Ferring patent: an idea on paper, with no data
Ferring B.V.’s application WO2023046336A1 (priority date 22 Sep 2021) covers aqueous nasal formulations of Semax[4]. In passing, it says Semax derivatives “may comprise an acetyl moiety, an amidate moiety, and an adamantane moiety”. The aim is to achieve or improve “increased halflife, increased blood-brain-barrier permeability, and increased resistance to degradation”. It names N-acetyl-Met-Glu-His-Phe-Pro-Gly-Pro-adamantane-CONH2 as an example[4]. All five worked examples (methionine, pH, sorbitol and EDTA stability, plus example formulations) concern “the peptide”, meaning Semax itself, and none tests a derivative[4]. Google Patents lists the European family member EP4404912A1 as “deemed to be withdrawn”, effective 29 November 2025, and the US member as abandoned[5].
Evidence status in one line: a withdrawn or abandoned patent family names the molecule, and a different peptide supports the design logic. No published experiment has tested Adamax itself.
Mechanism: what is evidenced and what is claimed
Semax’s known weak point is enzymatic degradation. Tissue studies show it is broken down from both ends, producing fragments such as HFPGP and MEHFP[9]. In one older study, aminopeptidase inhibition (bestatin) blocked about two-thirds of degradation, while an ACE inhibitor (lisinopril) blocked about 15%[10]. This explains why people cap the ends. N-acetylation targets aminopeptidases, and C-terminal amidation or a bulky adamantane targets carboxypeptidases. We cover the acetyl and amide caps in detail in our Semax vs N-Acetyl Semax Amidate guide.
| Claim you will see | Evidence type | Status |
|---|---|---|
| Semax is degraded by peptidases from both termini | Peer-reviewed tissue studies[9][10] | Supported (preclinical) |
| A C-terminal adamantane unit slows carboxypeptidase degradation | P021 data, different peptide[7] | Plausible, not shown for Semax |
| Adamax crosses the blood–brain barrier better than Semax | Patent aim statement only[4] | Unsupported: no data |
| Adamax is “stronger” or “longer-lasting” than Semax | Vendor and forum copy | Unsupported |
| Adamax works like bromantane or amantadine | Shared ring system only | Incorrect framing (see below) |
| Adamax is safe | None | Unknown; no toxicology published |
One more note on cLogP: higher calculated lipophilicity does not mean a molecule crosses the blood–brain barrier. A molecule over 1,000 Da with eleven nitrogens and many hydrogen-bond donors is far outside the usual small-molecule range, with or without a cage.
Adamantane ≠ bromantane ≠ amantadine: a disambiguation box
| Compound | What it is | Formula | Relation to Adamax |
|---|---|---|---|
| Adamantane | The bare C10 hydrocarbon cage | C10H16 | The ring system Version A carries |
| Amantadine | 1-aminoadamantane, a small-molecule drug[13] | C10H17N | Same cage, not a peptide |
| Memantine | 3,5-dimethyl-1-aminoadamantane[14] | C12H21N | Same cage, not a peptide |
| Bromantane | N-(4-bromophenyl)adamantan-2-amine[12] | C16H20BrN | Same cage, not a peptide; WADA S6 stimulant in-competition[15] |
| Adamax, Version A | Semax-derived peptide with a C-terminal adamantane carboxamide | C50H69N11O11S | — |
A molecule having an adamantane ring tells you nothing about what it does. Amantadine, memantine and bromantane are pharmacologically different from each other, and none of their data carry over to a peptide conjugate. On sport rules: WADA names bromantan, but neither Semax nor Adamax appears by name. The S0 section covers pharmacological substances with no current approval for human therapeutic use[15]. Whether a given product falls under S0 is for anti-doping authorities to decide. We are not giving guidance on that.
How to verify what’s in a vial: HPLC, LC-MS and the 0.98 Da trap

Purity and identity are different tests. HPLC-UV gives a percentage. It tells you how much of the UV signal sits in the main peak, not what that peak is. Identity needs mass spectrometry, ideally high-resolution, plus fragmentation when the stakes are high. Forensic labs examining seized “research peptides” rely on LC-MS for exactly this reason[11].
Expected masses (calculated)
| Species | Formula | [M+H]⁺ | [M+2H]²⁺ | [M+3H]³⁺ | What it means |
|---|---|---|---|---|---|
| Version A, amide (intended 1032) | C50H69N11O11S | 1032.4971 | 516.7522 | 344.8372 | Correct target |
| Version A, free acid | C50H68N10O12S | 1033.4812 | 517.2442 | 345.1652 | C-terminal amide missing (+0.984 Da) |
| Version A + oxidized Met | C50H69N11O12S | 1048.4921 | 524.7497 | 350.1689 | Met sulfoxide (+15.995 Da) |
| Version B (984) | C44H61N11O13S | 984.4244 | 492.7158 | 328.8130 | Different molecule |
| N-Acetyl Semax amidate | C39H54N10O10S | 855.3818 | 428.1945 | 285.7988 | No adamantane unit at all |
| Semax | C37H51N9O10S | 814.3552 | 407.6813 | 272.1233 | Unmodified parent |
The 0.98 Da trap. The amide and the free acid differ by 0.984 Da, which is very close to the spacing of the ¹³C isotope peaks (1.003 Da). On a low-resolution instrument, or a spectrum read only at the nominal mass, an acid impurity can hide inside the amide’s isotope envelope. Ask for high-resolution data or a separated chromatographic peak. This is the same issue we flag for N-Acetyl Semax Amidate.
Fragment ions that tell the versions apart (calculated)
All Ac-capped forms share the same b-ion ladder for the Ac-MEHFPGP core: b1 174.058, b2 303.101, b3 440.160, b4 587.228, b5 684.281, b6 741.303, b7 838.355. The C-terminus is what differs. Version A gives a y1 ion at 195.149 (the protonated adamantane carboxamide unit). Version B gives y1 76.039 (Gly) and y2 147.076 (Ala-Gly), plus b8 909.392. N-Acetyl Semax amidate stops at the Pro-NH2 end. If a lab’s MS/MS lacks the expected y1, the C-terminus has not been confirmed.
What a typical Adamax COA does and doesn’t prove
We read one publicly posted third-party COA for an “Adamax 10mg (1032)” lot. It reports 99.90% HPLC purity, a net peptide content of 10.34 mg, a heavy-metal ICP-MS panel and a fentanyl screen. Identity is given as “HPLC-RTM”, a retention-time match, with no mass spectrum[26]. Retention-time matching only shows that the sample elutes like a reference standard. It is only as good as that standard, and for a compound with no pharmacopoeial reference, that is circular. It cannot settle the amide/acid question or the 1032 vs 984 question. We are not criticizing that laboratory’s work. We are pointing out what this test format can and cannot show.
Converting labelled mg to molar amounts (calculated)
Version A is heavier, so 1 mg contains fewer molecules than 1 mg of Semax. Counter-ions reduce this further. For background on salts, see our TFA vs acetate salt guide.
| Form | nmol per mg, free base | with 1 TFA | with 2 TFA |
|---|---|---|---|
| Semax | 1229 | 1078 | 960 |
| Adamax Version A | 969 | 872 | 793 |
Decision tree: which question are you actually asking?
- Does your protocol need a molecule that has a literature behind it? → Semax. It’s the only one of the three with a registry identity and peer-reviewed data[1][9].
- Are you studying end-capping and degradation? → N-Acetyl Semax amidate is the documented capped form, with a PubChem record[2]. See the comparison guide.
- Are you specifically testing a C-terminal adamantane conjugate? → Then you are characterizing a new compound. Before any experiment: (a) obtain a drawn structure and formula from the supplier; (b) confirm it is C50H69N11O11S with [M+H]⁺ 1032.497 or [M+2H]²⁺ 516.752 on HRMS; (c) rule out the free acid (1033.481) and Met oxidation (1048.492); (d) confirm y1 195.149 by MS/MS; (e) record net peptide content.
- Did your vial arrive as “Adamax” with a mass near 984? → You have Version B, an extended peptide with no adamantane. Treat it as a different compound and label it that way in your records.
- Does the COA show HPLC only, or identity by HPLC-RTM? → Purity is documented, but identity is not. Request LC-MS before using the material in anything you intend to publish.
Myth vs evidence
| Myth | What the record shows |
|---|---|
| “Adamax is a studied Semax analogue.” | No peer-reviewed paper and no registered trial found[17][18]. |
| “It’s patented by a major pharma company, so it’s validated.” | A patent application named it without testing it. The EP member is deemed withdrawn and the US member abandoned[4][5]. |
| “The adamantane makes it cross the blood–brain barrier.” | That is the stated aim in the patent and P021 papers. It hasn’t been measured for any Semax conjugate[4][7]. |
| “All Adamax is the same molecule.” | At least two structures, 48 Da apart (calculated)[3]. |
| “It contains adamantylglycine.” | The quoted formula fits 3-amino-adamantane-1-carboxamide instead (calculated)[8]. |
| “99.9% HPLC means it’s the right compound.” | Purity is not identity. Retention-time matching can’t tell isobaric or near-isobaric variants apart[26][11]. |
| “Adamax raises BDNF and is more dopaminergic than Semax.” | Those findings come from Semax experiments[23]. Nobody has tested Adamax. |
| “Adamax is a vasopressin/oxytocin/BPC-157 blend.” | No published formula supports this; both circulating structures are Semax-derived (see the structure table). |
| “Semax weighs about 888 Da; the acetyl form about 930 Da.” | Semax is 813.9 g/mol (PubChem). N-acetyl Semax is about 856 g/mol, and N-acetyl Semax amidate 855.0[1][2]. |
| “Ac-MEHFPGPAG-NH2, formula C50H69N11O11S.” | That pairing, seen in an encyclopedia infobox, is internally inconsistent. Ac-MEHFPGPAG-NH2 would be C44H62N12O12S, about 983.1 g/mol (calculated). C50H69N11O11S is the adamantane version[25]. |
| “Adamax has been seized at the border.” | Medsafe reports intercepting peptide parcels. It says unscheduled peptides were released with a warning letter because it lacked grounds to seize them[19]. |
| “FDA removed Semax from Category 2, so it’s cleared.” | The nominations were withdrawn. FDA’s entry still describes immunogenicity risk and limited safety data, and an advisory-committee discussion is not approval[16][21]. |
| “It’s basically bromantane plus Semax.” | Bromantane is a separate small molecule. Sharing a ring system doesn’t mean shared pharmacology[12]. |
Glossary
- Adamantane: a rigid, diamond-like C10H16 hydrocarbon cage. In Chinese it is 金刚烷 (literally “diamond alkane”).
- Amidate / C-terminal amide: replacing the terminal –COOH with –CONH2. This removes a negative charge and can slow carboxypeptidases.
- N-acetylation: capping the N-terminal amine with an acetyl group. This can slow aminopeptidases.
- Carboxypeptidase / aminopeptidase: enzymes that trim peptides from the C- or N-terminus.
- Monoisotopic mass: the mass using the most abundant isotope of each element. This is the number HRMS compares against.
- [M+2H]²⁺: a doubly protonated ion, observed at roughly half the mass.
- HPLC-RTM: identity claimed by retention-time match to a reference. It is not structural proof.
- Net peptide content (NPC): the actual peptide mass in the vial after subtracting water and counter-ions.
- cLogP: a calculated lipophilicity estimate. It is not a measured property.
- WADA S0: the Prohibited List section covering non-approved pharmacological substances.
Frequently asked questions
What does the peptide Adamax do?
No one has published a measurement. No binding, cell, animal or human study of Adamax was found as of 30 October 2026. Claims that it raises BDNF or is “more dopaminergic” are carried over from Semax research, not tested on Adamax.
What is the difference between Adamax and Semax?
Semax is a registered seven-residue ACTH(4-7)-Pro-Gly-Pro peptide (813.9 g/mol) with a published, mostly Russian, literature. Adamax is a market name for modified Semax. It is sold either with an acetyl cap and C-terminal adamantane carboxamide (about 1032 g/mol) or with an Ala-Gly extension (about 984 g/mol), and it has no published studies.
What are Adamax peptide side effects?
No human safety data exist for Adamax. New Zealand’s Medsafe notes that little is known about the side effects or long-term effects of ACTH analogues as a class. Side-effect lists online are borrowed from Semax or user self-reports.
What is Semax similar to?
Structurally, Semax is closest to its capped forms (N-acetyl Semax amidate), to Adamax, and to Selank, which shares its Pro-Gly-Pro tail but is built on tuftsin (Thr-Lys-Pro-Arg) instead of the ACTH(4-7) fragment.
Which is better, Semax or Selank?
There is no general answer. They share only the Pro-Gly-Pro tail and come from different parent fragments, ACTH versus tuftsin, so their research literatures address different questions. This reference does not make therapeutic comparisons.
Is there evidence for Semax for ADHD, anxiety or energy?
We found no registered trial of Semax on ClinicalTrials.gov. The ADHD idea traces to a 2007 hypothesis paper that proposed, but did not test, Semax for ADHD based on animal data. We do not evaluate therapeutic uses; this reference covers chemistry and evidence status only.
What is Adamax peptide?
Adamax is a market name for Semax-derived peptides, not a registered compound. It is sold as either Ac-MEHFPGP with a C-terminal adamantane carboxamide (~1032 Da) or Ac-MEHFPGPAG-OH (~984 Da). No peer-reviewed study on either was found.
Is Adamax the same as Semax?
No. Both share the Met-Glu-His-Phe-Pro-Gly-Pro core, but Adamax adds an N-terminal acetyl group and either an adamantane unit or an Ala-Gly extension. That makes it a different molecule with a different mass and no published data.
Is Adamax better or stronger than Semax?
There is no evidence either way. No published study compares them, and claims of greater potency or duration come from vendor copy, not data.
What does Adamax 1032 mean?
1032 refers to the approximate molecular weight (calculated 1032.23 g/mol) of the adamantane-conjugated version, C50H69N11O11S. It distinguishes it from the 984 Da Ala-Gly version sold under the same name.
Is Adamax related to bromantane, amantadine or memantine?
Only in sharing the adamantane ring system. Those are small-molecule drugs or stimulants with their own pharmacology, and none of their data apply to a Semax peptide conjugate.
Are there clinical trials on Adamax?
None were found on ClinicalTrials.gov or PubMed as of 30 October 2026.
Is Adamax legal or WADA-banned?
WADA’s 2026 list does not name Adamax or Semax; it names bromantan under S6, and S0 covers non-approved substances in general. New Zealand’s Medsafe has proposed classifying ACTH analogues, naming Adamax, as prescription medicines, with a decision deferred in July 2025. Legal status depends on the jurisdiction, and this article does not provide legal advice.
How can a lab confirm Adamax identity?
By high-resolution LC-MS. The 1032 amide should give [M+H]+ 1032.497 or [M+2H]2+ 516.752 (calculated). The lab should also rule out the free acid at 1033.481 and Met oxidation at 1048.492. HPLC purity or retention-time match alone does not prove identity.
Related reading
- Semax vs N-Acetyl Semax Amidate: structure, stability and verification
- Selank vs N-Acetyl Selank Amidate
- TFA vs acetate peptide salts
- TB-500 fragment vs full-length Thymosin β4
Methods and limitations
Searched 30 October 2026: PubMed, Europe PMC, ClinicalTrials.gov, PubChem, FDA GSRS, FDA compounding pages, Medsafe and Google Patents. We also read the pages ranking in Google’s top results for “adamax vs semax”, “adamax peptide” and “adamax semax difference” (captured 30 October 2026) and traced their factual claims back to sources; claims we could not source are flagged above. Primary sources were read in full except where marked abstract-only. All masses, formulas, fragment ions, cLogP and nmol/mg values are our own calculations (RDKit and standard monoisotopic masses) and should be checked against a lab’s observed data. Retail descriptions were used only to establish what is being sold, never as evidence of effect. Limitations: unpublished in-house data may exist, and supplier structures may change without notice.
Related research: Adamax Research Material丨What Is Known and What Must Be Batch-Verified; Semax vs N-Acetyl Semax vs N-Acetyl Semax Amidate: Structure, Mass, MS/MS Identity, Degradation and Salt Forms; What Is Semax; Semax.
About the author: the SaiyanMed Research Team writes reference content for laboratory researchers. All products and information are for research use only, not for human consumption, and are not intended to diagnose, treat, cure or prevent any disease.
References
- PubChem CID 9811102 — Semax (C37H51N9O10S). Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/9811102
- PubChem CID 172638603 — N-Acetyl Semax amidate. Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/172638603
- PubChem SID 513899171 — vendor-deposited substance record with synonym “Adamax” (no structure deposited). Registry record (depositor-supplied). https://pubchem.ncbi.nlm.nih.gov/substance/513899171
- Ferring B.V. WO2023046336A1 — aqueous nasal Semax compositions (full text read). Patent application. https://patents.google.com/patent/WO2023046336A1/en
- EP4404912A1 — European family member; legal status “deemed to be withdrawn”, effective 29 Nov 2025. Patent legal status. https://patents.google.com/patent/EP4404912A1/en
- Li B, Wanka L, Blanchard J, et al. FEBS Lett. 2010;584:3359–65 (abstract only). Peer-reviewed, abstract only. https://pubmed.ncbi.nlm.nih.gov/20600002/
- Baazaoui N, Iqbal K, et al. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017 (full text read). Peer-reviewed, mouse study. https://pmc.ncbi.nlm.nih.gov/articles/PMC5488423/
- FDA GSRS — P-21 (C27H42N6O8). Registry record. https://gsrs.ncats.nih.gov/ginas/app/ui/substances/6db56abb-57cb-4e61-9029-7f64a862f2c1
- Zolotarev YA, et al. Semax degradation in nervous tissue, 2006. Peer-reviewed. https://pubmed.ncbi.nlm.nih.gov/16773243/
- Potaman VN, et al. Semax degradation and peptidase inhibitors, 1993. Peer-reviewed. https://pubmed.ncbi.nlm.nih.gov/8392718/
- Vanhee C, Janvier S, Deconinck E, et al. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations. Drug Test Anal. 2020; doi:10.1002/dta.2717 (Sciensano PDF). Government lab report. https://sciensano.be/sites/default/files/dta_nootropic_peptides.pdf
- PubChem CID 4660557 — Bromantane. Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/4660557
- PubChem CID 2130 — Amantadine. Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/2130
- PubChem CID 4054 — Memantine. Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/4054
- WADA 2026 Prohibited List (PDF). Regulatory list. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf
- U.S. FDA — Certain bulk drug substances for use in compounding that may present significant safety risks. Regulator page. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- PubMed search “adamax” (searched 30 Oct 2026). Database search. https://pubmed.ncbi.nlm.nih.gov/?term=adamax
- ClinicalTrials.gov search “adamax” (searched 30 Oct 2026). Database search. https://clinicaltrials.gov/search?term=adamax
- Medsafe (New Zealand). Classification of Unscheduled Peptides — submission to the Medicines Classification Committee, June 2025 (full text read). Regulator document. https://www.medsafe.govt.nz/profs/class/Agendas/Agen74/5.7Peptides.pdf
- Medsafe. Minutes of the 74th meeting of the Medicines Classification Committee, 23 July 2025 (item 5.7). Regulator minutes. https://www.medsafe.govt.nz/profs/class/Minutes/2021-2025/74mccMin23July2025.htm
- U.S. FDA — July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. Regulator page. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- PubChem CID 11765600 — Selank (C33H57N11O9). Registry record. https://pubchem.ncbi.nlm.nih.gov/compound/11765600
- Tsai SJ. Semax, an analogue of adrenocorticotropin (4-10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome. Med Hypotheses. 2007;68:1144–6. Hypothesis paper, no new data (abstract read). https://pubmed.ncbi.nlm.nih.gov/16996699/
- ClinicalTrials.gov search “semax” (searched 30 Oct 2026). Database search. https://clinicaltrials.gov/search?term=semax
- Wikipedia — “Adamax” (revision of 3 May 2026). Encyclopedia entry (cited as an example of a conflicting source). https://en.wikipedia.org/wiki/Adamax
- Example third-party COA, “Adamax 10mg (1032)”, lot CR-ADMX1032-0916. Lab document (single example; publicly posted PDF, link intentionally omitted; read 30 Oct 2026).